Clinical trials: Primary Mediastinal B Cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children and adolescent with primary mediastinal large B cell lymphoma in terms of event free survival.
- Trial name
- NCT01516567
- Testing
- Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab
- Where
- 9 sites in Belgium, Canada and 7 more
- Volunteers
- 47 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04002622
- Testing
- TQB2450
- Where
- 18 sites in China
- Volunteers
- 1 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lymphoma, Follicular, Lymphoma, Mantle-Cell
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- NCT04911478
- Testing
- ADI-001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Adicet Therapeutics
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers
The purpose of this study is to test the safety of 19(T2)28z1xx CAR T cells in people with relapsed/refractory B-cell cancers. The researchers will try to find the highest dose of 19(T2)28z1xx CAR T cells that causes few or mild…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT04464200
- Testing
- 19(T2)28z1xx CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
The goal of this clinical trial is to learn if a new type of chimeric antigen receptor (CAR) T-cell therapy called atlacabtagene autoleucel is effective and safe for the treatment large B-cell lymphomas (LBCL) that have not…
- Conditions
- Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Non-Hodgkin Lymphoma
- Trial name
- ENABLE-2 (NCT06486051)
- Testing
- Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells
- Where
- 3 sites in New Zealand
- Volunteers
- 60 people
- Sponsor
- Malaghan Institute of Medical Research
B-cell Lymphoma, Non Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of CD20-expressing B-cell malignancies.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT05653271
- Testing
- Cyclophosphamide, Fludarabine, ACE1831
- Where
- 13 sites in United States, Hong Kong and 1 more
- Volunteers
- 16 people
- Sponsor
- Acepodia Biotech, Inc.
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
- Conditions
- Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL)
- Trial name
- NCT04745559
- Testing
- Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
DLBCL, High-grade B-cell Lymphoma (HGBCL)
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): The dose schedule…
- Conditions
- DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
- Trial name
- EPCORE™ NHL-1 (NCT03625037)
- Testing
- Epcoritamab
- Where
- 85 sites in United States, Australia and 13 more
- Volunteers
- 666 people
- Sponsor
- Genmab
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
This study is designed to monitor all patients exposed to CD19 CAR-T expressing IL7 and CCL19 for 5 years following infusion, to assess their long-term efficacy, including the CAR-vector persistence, the normal immunity…
- Conditions
- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Transformed Follicular Lymphoma, Primary Mediastinal Large B-cell Lymphoma
- Trial name
- NCT04833504
- Testing
- CD19 CAR-T Expressing IL7 and CCL19
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL
This is a phase 2 study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ibrutinib), in combination with bendamustine and rituximab (BR) in subjects with previously treated aggressive B cell non Hodgkin lymphoma (aB-NHL)…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma, Recurrent Disease
- Trial name
- NCT02747732
- Testing
- Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
- Where
- 2 sites in Israel
- Volunteers
- 72 people
- Sponsor
- Meirav Kedmi MD
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
This is an observational, multicenter, prospective cohort study including patients treated with CAR-T in Italian centers. Patients eligible for enrollment in the study will be consecutively included in Italian FIL centers.
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- NEURO_CAR-T (NCT07463781)
- Testing
- Chimeric Antigen Receptor T-cells (CAR-T) therapy
- Where
- 8 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of…
- Conditions
- Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma
- Trial name
- NCT05826535
- Testing
- Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide
- Where
- 35 sites in United States, Australia
- Volunteers
- 270 people
- Sponsor
- Lyell Immunopharma, Inc.
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- PROSECO (NCT04858568)
- Where
- 9 sites in United Kingdom
- Volunteers
- 592 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell…
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- EPCORE™ NHL-3 (NCT04542824)
- Testing
- Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- Where
- 15 sites in Japan
- Volunteers
- 78 people
- Sponsor
- Genmab
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma
- Trial name
- NCT06784726
- Testing
- Odronextamab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Lymphoma
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00983944
- Testing
- bleomycin sulfate, rituximab, EPOCH regimen
- Sponsor
- Ohio State University Comprehensive Cancer Center
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
CD19 Positive, CD20 Positive
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial studies the side effects and best dose of CD19/CD20 chimeric antigen receptor (CAR) T-cells when given together with chemotherapy, and to see how effective they are in treating patients with non-Hodgkin's…
- Conditions
- CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04007029
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05169489
- Testing
- bbT369
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Regeneron Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.